Trial · NCT00307047
Results by group132
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 132
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Ischemia Driven Target Vessel Failure (TVF) | XIENCE V® | 1.9 | percentage of participants | ||
| Ischemia Driven Target Vessel Failure (TVF) | TAXUS™ EXPRESS 2™ | 3.1 | percentage of participants | ||
| Ischemia Driven Target Vessel Failure (TVF) | XIENCE V® | 3.4 | percentage of participants | ||
| Ischemia Driven Target Vessel Failure (TVF) | TAXUS™ EXPRESS 2™ | 6.2 | percentage of participants | ||
| Ischemia Driven Target Vessel Failure (TVF) | XIENCE V® | 4.6 | percentage of participants | ||
| Ischemia Driven Target Vessel Failure (TVF) | TAXUS™ EXPRESS 2™ | 7.2 | percentage of participants | ||
| Ischemia Driven Target Vessel Failure (TVF) | XIENCE V® | 5.6 | percentage of participants | ||
| Ischemia Driven Target Vessel Failure (TVF) | TAXUS™ EXPRESS 2™ | 7.9 | percentage of participants | ||
| Ischemia Driven Target Vessel Failure (TVF) | XIENCE V® | 9.6 | percentage of participants | ||
| Ischemia Driven Target Vessel Failure (TVF) | TAXUS™ EXPRESS 2™ | 11.8 | percentage of participants | ||
| Ischemia Driven Target Vessel Failure (TVF) | XIENCE V® | 13.3 | percentage of participants | ||
| Ischemia Driven Target Vessel Failure (TVF) | TAXUS™ EXPRESS 2™ | 14.5 | percentage of participants | ||
| Ischemia Driven Target Lesion Revascularization (TLR) | XIENCE V® | 0.4 | percentage of participants | ||
| Ischemia Driven Target Lesion Revascularization (TLR) | TAXUS™ EXPRESS 2™ | 1.1 | percentage of participants | ||
| Ischemia Driven Target Lesion Revascularization (TLR) | XIENCE V® | 1.1 | percentage of participants | ||
| Ischemia Driven Target Lesion Revascularization (TLR) | TAXUS™ EXPRESS 2™ | 3.2 | percentage of participants | ||
| Ischemia Driven Target Lesion Revascularization (TLR) | XIENCE V® | 1.9 | percentage of participants | ||
| Ischemia Driven Target Lesion Revascularization (TLR) | TAXUS™ EXPRESS 2™ | 4.1 | percentage of participants | ||
| Ischemia Driven Target Lesion Revascularization (TLR) | XIENCE V® | 2.5 | 1.94 to 3.23 | percentage of participants | |
| Ischemia Driven Target Lesion Revascularization (TLR) | TAXUS™ EXPRESS 2™ | 4.6 | 3.49 to 5.95 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00307047/results